Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 8/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PYGB | P11216 | 3/20 | 0.31 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.30 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.30 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.30 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18789291 | 1.00 | CDA (0.35) | CDAPDE4DPDE3ASLC29A1ALDH1A1 | |
| SCHEMBL8857031 | 1.00 | CDA (0.35) | CDAPDE4DPDE3ASLC29A1ALDH1A1 | |
| SCHEMBL8857040 | 1.00 | CDA (0.35) | CDAPDE4DPDE3ASLC29A1ALDH1A1 | |
| SCHEMBL17610102 | 0.87 | LGALS1 (0.36) | ALDH1A1TSHRLMNATDP1PYGB | |
| SCHEMBL6837637 | 0.87 | LGALS1 (0.36) | ALDH1A1TSHRLMNATDP1PYGB | |
| SCHEMBL6837636 | 0.87 | LGALS1 (0.36) | ALDH1A1TSHRLMNATDP1PYGB | |
| SCHEMBL27818667 | 0.87 | LGALS1 (0.36) | ALDH1A1TSHRLMNATDP1PYGB | |
| SCHEMBL14416499 | 0.79 | CDA (0.42) | CDAPDE4DPDE3ASLC29A1ALDH1A1 | |
| SCHEMBL3359938 | 0.79 | CDA (0.42) | CDAPDE4DPDE3ASLC29A1ALDH1A1 | |
| SCHEMBL15603335 | 0.79 | CDA (0.42) | CDAPDE4DPDE3ASLC29A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2976351-B1 | LIPOHILLIC OLIGONUCLEOTIDE ANALOGS | MILTENYI BIOTEC GMBH (DE) | 2018-02-21 | — | — | EP | disclosed |
| US-9803198-B2 | Lipohillic oligonucleotide analogs | MILTENYI BIOTEC, GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| EP-2976351-A1 | LIPOHILLIC OLIGONUCLEOTIDE ANALOGS | Miltenyi Biotec GmbH (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-20160017325-A1 | LIPOHILLIC OLIGONUCLEOTIDE ANALOGS | MILTENYI BIOTEC GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| US-9156875-B2 | Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties | ADIUTIDE PHARMACEUTICALS GMBH (DE) | 2015-10-13 | — | — | US | disclosed |
| EP-2883957-A1 | Immunostimmulatory oligoribonucleotides | Zoetis Belgium S.A. (BE) | 2015-06-17 | — | — | EP | disclosed |
| EP-1957647-B1 | IMMUNOSTIMULATORY OLIGORIBONUCLEOTIDES | ZOETIS BELGIUM S A (BE) | 2015-03-04 | — | — | EP | disclosed |
| EP-2207787-B1 | IMMUNE STIMULATORY OLIGORIBONUCLEOTIDE ANALOGS CONTAINING MODIFIED OLIGOPHOSPHATE MOIETIES | ADIUTIDE PHARMACEUTICALS GMBH (DE) | 2014-11-12 | — | — | EP | disclosed |
| WO-2014147095-A1 | LIPOHILLIC OLIGONUCLEOTIDE ANALOGS | MILTENYI BIOTEC GMBH (DE) | 2014-09-25 | — | — | WO | disclosed |
| EP-2781523-A1 | Lipophilic oligonucleotide analogs | Miltenyi Biotec GmbH (DE) | 2014-09-24 | — | — | EP | disclosed |
| EP-2104738-A2 | OLIGORIBONUCLEOTIDES AND USES THEREOF | Coley Pharmaceuticals GmbH (DE) | 2009-09-30 | — | — | EP | disclosed |
| WO-2009060281-A2 | IMMUNE STIMULATORY OLIGORIBONUCLEOTIDE ANALOGS CONTAINING MODIFIED OLIGOPHOSPHATE MOIETIES | COLEY PHARMACEUTICAL GMBH (DE) | 2009-05-14 | — | — | WO | disclosed |
| WO-2008139262-A2 | OLIGORIBONUCLEOTIDES AND USES THEREOF | COLEY PHARMACEUTICAL GMBH (DE) | 2008-11-20 | — | — | WO | disclosed |
| EP-1957647-A2 | IMMUNOSTIMULATORY OLIGORIBONUCLEOTIDES | Coley Pharmaceutical GmbH (DE) | 2008-08-20 | — | — | EP | disclosed |
| WO-2008033432-A2 | IMMUNE MODULATION BY CHEMICALLY MODIFIED RIBONUCLEOSIDES AND OLIGORIBONUCLEOTIDES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1899467-A2 | MODIFIED OLIGORIBONUCLEOTIDE ANALOGS WITH ENHANCES IMMUNOSTIMULATORY ACTIVITY | Coley Pharmaceutical GmbH (DE) | 2008-03-19 | — | — | EP | disclosed |
| US-20070142315-A1 | Immunostimulatory oligoribonucleotides | COLEY PHARMACEUTICAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| WO-2007062107-A2 | IMMUNOSTIMULATORY OLIGORIBONUCLEOTIDES | COLEY PHARMACEUTICAL GMBH (DE) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006116458-A2 | MODIFIED OLIGORIBONUCLEOTIDE ANALOGS WITH ENHANCES IMMUNOSTIMULATORY ACTIVITY | COLEY PHARMACEUTICAL GMBH (DE) | 2006-11-02 | — | — | WO | disclosed |
| US-20060241076-A1 | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity | COLEY PHARMACEUTICAL GMBH (DE) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142315-A1 | Immunostimulatory oligoribonucleotides | TLR9, TLR8, TLR3 | CDA 382/4885PDE4D 397/4885PDE3A 1948/4885 |
| US-20060241076-A1 | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity | TLR3, TLR8, TLR9 | CDA 232/4885PDE4D 353/4885PDE3A 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.